{"id":36024,"date":"2025-10-21T11:01:56","date_gmt":"2025-10-21T09:01:56","guid":{"rendered":"https:\/\/ggba.swiss\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/"},"modified":"2025-10-21T11:10:00","modified_gmt":"2025-10-21T09:10:00","slug":"adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/","title":{"rendered":"ADC Therapeutics l\u00e8ve USD 60 millions pour renforcer son portefeuille en oncologie"},"content":{"rendered":"\n

Pionni\u00e8re mondiale dans le domaine des conjugu\u00e9s anticorps-m\u00e9dicament (ADCs), ADC Therapeutics<\/a> a annonc\u00e9 une lev\u00e9e de fonds de USD 60 millions dans le cadre d\u2019un placement priv\u00e9 (\u00ab PIPE \u00bb) pour soutenir sa prochaine phase de croissance. Bas\u00e9e sur le campus Biop\u00f4le<\/a> \u00e0 Lausanne, l\u2019entreprise d\u00e9veloppe un portefeuille de th\u00e9rapies cibl\u00e9es en oncologie visant \u00e0 am\u00e9liorer les r\u00e9sultats pour les patients atteints de cancers difficiles \u00e0 traiter.<\/p>\n\n\n\n

Le tour de financement est men\u00e9 par TCGX<\/a>, avec la participation de Redmile Group<\/a> et d\u2019autres investisseurs existants. ADC Therapeutics \u00e9mettra 11,3 millions d\u2019actions ordinaires \u00e0 USD 4,00 par action et 3,8 millions de bons de souscription \u00e0 USD 3,90 chacun. L\u2019op\u00e9ration, dont la cl\u00f4ture est pr\u00e9vue le 27 octobre 2025, devrait g\u00e9n\u00e9rer environ USD 57,6 millions de produits nets apr\u00e8s d\u00e9duction des frais.<\/p>\n\n\n\n

Les fonds serviront \u00e0 soutenir l\u2019expansion commerciale de ZYNLONTA\u00ae<\/a>, le traitement approuv\u00e9 par la FDA et l\u2019EMA pour le lymphome \u00e0 grandes cellules B en rechute ou r\u00e9fractaire, et \u00e0 renforcer la position financi\u00e8re de la soci\u00e9t\u00e9 en vue d\u2019un possible relancement en 2027.
\u00ab Ce financement renforce notre capacit\u00e9 \u00e0 pr\u00e9parer et ex\u00e9cuter le relancement potentiel de ZYNLONTA, tout en consolidant notre bilan \u00bb, a d\u00e9clar\u00e9 Ameet Mallik, CEO d\u2019ADC Therapeutics. \u00ab Nous estimons \u00eatre bien positionn\u00e9s pour acc\u00e9l\u00e9rer notre trajectoire vers une croissance durable \u00e0 long terme. \u00bb<\/p>\n\n\n\n

Un p\u00f4le de recherche avanc\u00e9e en canc\u00e9rologie et en m\u00e9decine de pr\u00e9cision<\/h4>\n\n\n\n

ZYNLONTA, le produit phare de la soci\u00e9t\u00e9, est le premier et unique ADC dirig\u00e9 contre CD19 approuv\u00e9 pour les patients adultes ayant re\u00e7u deux lignes de traitement ou plus. En combinant un anticorps ciblant les prot\u00e9ines de surface des cellules B \u00e0 une charge cytotoxique puissante, ZYNLONTA permet une destruction cibl\u00e9e des cellules canc\u00e9reuses tout en limitant les effets ind\u00e9sirables sur les tissus sains.<\/p>\n\n\n\n

Fond\u00e9e en 2011 et bas\u00e9e dans le canton de Vaud, ADC Therapeutics illustre la force de la Suisse occidentale dans l\u2019innovation en oncologie. Sa pr\u00e9sence au sein de l\u2019\u00e9cosyst\u00e8me Biop\u00f4le, qui abrite un cluster croissant de soci\u00e9t\u00e9s biotechnologiques et medtech, renforce la r\u00e9putation de la r\u00e9gion comme p\u00f4le europ\u00e9en de la recherche avanc\u00e9e sur le cancer et de la m\u00e9decine de pr\u00e9cision.<\/p>\n","protected":false},"excerpt":{"rendered":"

La biotech lausannoise ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.<\/p>\n","protected":false},"author":6,"featured_media":36028,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1202,1188,1140,1142,1168],"class_list":["post-36024","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-headquarters-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2","tag-rd-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"\nADC Therapeutics l\u00e8ve USD 60 millions | GGBa<\/title>\n<meta name=\"description\" content=\"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics l\u00e8ve USD 60 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T09:01:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T09:10:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1520\" \/>\n\t<meta property=\"og:image:height\" content=\"936\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ADC Therapeutics l\u00e8ve USD 60 millions pour renforcer son portefeuille en oncologie\",\"datePublished\":\"2025-10-21T09:01:56+00:00\",\"dateModified\":\"2025-10-21T09:10:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\"},\"wordCount\":407,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Headquarters\",\"Healthcare\",\"Oncology\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\",\"name\":\"ADC Therapeutics l\u00e8ve USD 60 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"datePublished\":\"2025-10-21T09:01:56+00:00\",\"dateModified\":\"2025-10-21T09:10:00+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"width\":1520,\"height\":936,\"caption\":\"Les conjugu\u00e9s anticorps-m\u00e9dicament (ADCs) d\u2019ADC Therapeutics offrent une th\u00e9rapie anticanc\u00e9reuse cibl\u00e9e en associant des anticorps monoclonaux \u00e0 des agents cytotoxiques puissants. | \u00a9 ADC Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics l\u00e8ve USD 60 millions pour renforcer son portefeuille en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics l\u00e8ve USD 60 millions | GGBa","description":"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/","og_locale":"fr_FR","og_type":"article","og_title":"ADC Therapeutics l\u00e8ve USD 60 millions | GGBa","og_description":"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.","og_url":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-21T09:01:56+00:00","article_modified_time":"2025-10-21T09:10:00+00:00","og_image":[{"width":1520,"height":936,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ADC Therapeutics l\u00e8ve USD 60 millions pour renforcer son portefeuille en oncologie","datePublished":"2025-10-21T09:01:56+00:00","dateModified":"2025-10-21T09:10:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/"},"wordCount":407,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","keywords":["Biotech","Financing","Headquarters","Healthcare","Oncology","R&D","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/","url":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/","name":"ADC Therapeutics l\u00e8ve USD 60 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","datePublished":"2025-10-21T09:01:56+00:00","dateModified":"2025-10-21T09:10:00+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ADC Therapeutics a lev\u00e9 USD 60 millions afin de soutenir la commercialisation \u00e9largie de son traitement anticanc\u00e9reux ZYNLONTA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","width":1520,"height":936,"caption":"Les conjugu\u00e9s anticorps-m\u00e9dicament (ADCs) d\u2019ADC Therapeutics offrent une th\u00e9rapie anticanc\u00e9reuse cibl\u00e9e en associant des anticorps monoclonaux \u00e0 des agents cytotoxiques puissants. | \u00a9 ADC Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-leve-usd-60-millions-pour-renforcer-son-portefeuille-en-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics l\u00e8ve USD 60 millions pour renforcer son portefeuille en oncologie"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=36024"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36024\/revisions"}],"predecessor-version":[{"id":36026,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36024\/revisions\/36026"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/36028"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=36024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=36024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=36024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}